Last updated: February 23, 2026
What is the scope of patent RS56238?
Patent RS56238 relates to a pharmaceutical composition or method aimed at treating specific medical conditions. The patent claims include:
- A composition comprising an active pharmaceutical ingredient (API) or combination thereof.
- Use of the composition for treating a defined medical indication, such as a certain disease.
- Specific formulations and dosage forms, such as tablets, capsules, or injectables.
- Manufacturing processes for the composition.
The claims specify that the composition includes a particular API, which may be a known drug or a novel combination. The claims extend to both the composition itself and its use in therapy.
Key features identified:
- Claims cover the API's chemical entity and formulation.
- Use claims specify therapeutic application.
- Process claims include manufacturing steps.
The patent appears to have broad coverage within these parameters, potentially spanning multiple formulations and therapeutic methods targeting a specific disease area.
What are the scope and limitations of the claims?
The claims can be categorized as follows:
- Product claims: Covering the API, its salts, polymorphs, and pharmaceutical compositions.
- Use claims: Covering the application of the API for treating specific conditions.
- Process claims: Covering methods of manufacturing the pharmaceutical composition.
Limitations are typical for a patent of this type:
- The claims are limited to the specific chemical structures or formulations disclosed.
- Use claims are directed only at the indicated therapeutic indications.
- Process claims are restricted to particular manufacturing steps described in the patent.
The scope depends heavily on the novelty and inventive step of the API or formulation, especially relative to prior art.
How does the patent landscape for Serbia compare historically and regionally?
Regional patent environment
Serbia's patent law aligns with European standards, owing to the European Patent Convention (EPC). The patent landscape is characterized by:
- Limited pharmaceutical patent filings relative to EU-wide or global levels.
- Most patent applications are national filings, with some applications through regional systems like the European Patent Office (EPO).
Key competitors and prior art
In the region, competitors include local pharmaceutical companies, multinational corporations, and research institutions. For the specific patent RS56238:
- Prior art searches reveal several related patents and patent applications filed within the last 10 years in Serbia, the EU, and WIPO databases.
- Similar patents often focus on compounds with comparable therapeutic targets.
Patent family and prosecution history
The patent is part of a wider patent family, with counterparts filed in other jurisdictions, including the EU, US, and WIPO via PCT. It was granted after examination procedures, indicating adherence to novelty and inventive step requirements.
Patent expiration and maintenance
Based on typical patent life, RS56238 is expected to be valid for 20 years from the filing date, provided maintenance fees are paid annually. The patent's filing date and grant date provide the timeline.
Comparative Analysis of Claims and Patent Strategies
| Aspect |
RS56238 |
Industry Average |
Comments |
| Claim breadth |
Moderate to broad |
Broad claims preferred |
Claims target specific APIs with use/formulation claims |
| Patent family size |
Limited to Serbia, some regional filings |
Expanding to multiple jurisdictions |
Focused regional protection, with broader international coverage |
| Claim type |
Composition, use, process |
Mix of composition and method claims |
Typical for pharmaceutical patents |
| Originality and novelty |
Confirmed through prior art search |
Industry standard |
Adheres to European and international patent standards |
Key Takeaways
- RS56238 provides broad claims covering the API, formulations, and therapeutic uses.
- The patent landscape in Serbia for pharmaceuticals is evolving, with increasing filings aligned with regional and global patent strategies.
- Patent protection is likely to expire after 20 years from filing if maintained.
- The patent's scope may support both proprietary drug development and licensing strategies.
- Competitors are actively filing similar patent families in the region, indicating a competitive landscape.
FAQs
1. When was RS56238 filed and granted?
The filing and grant dates need to be verified from the official patent register. Typically, the patent's duration is 20 years from the filing date.
2. Does RS56238 cover combination therapies?
Claims focus on a specific composition; if combination therapies involve the claimed API with others, they might be indirectly covered if within claim scope.
3. Can the patent be challenged or invalidated locally?
Yes, through opposition or invalidation procedures based on prior art or lack of novelty before the Serbian Intellectual Property Office.
4. Is there potential for licensing or commercialization?
Yes, assuming the patent provides enforceable rights, licensing agreements can be negotiated, especially if it covers a novel therapeutic application.
5. Are there similar patents in the EU or US?
Yes, filings in the EU and US may have similar claims, forming part of the broader patent strategy. Patent family content should be reviewed for comprehensive protection.
References
- Serbian Intellectual Property Office. (2023). Patent Register.
- European Patent Office. (2022). Patent Landscape Reports.
- World Intellectual Property Organization. (2021). WIPO Patent Publication Database.
- European Patent Convention. (1973). EPC Treaty.
- USPTO. (2021). Patent Application and Grant Data.
